Consequently, several well-controlled retrospective analyses (32–35) and the prospective phase 3 clinical trial ALTA-1L (36) have demonstrated a more aggressive clinical course and shorter survival for EML4-ALK V3+ patients, while metastatic EGFR+ NSCLC appears to be prognostically homogenous regardless of the metastatic disparities between the de novo and secondary setting. This evidence concerns the gene ALK and non-small cell lung carcinoma.